CGON

Cg Oncology Inc

May 19 • 04:00PM ET

63.30

+0.37 0.59 %

Healthcare • Biotechnology • USA • Mid • NASD

| Held by: VTI VB XBI IWM VBR VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.34	Insider Own	33.67%	Shs Outstand	88.01M	Perf Week	-12.17%
Market Cap	5.58B	Forward P/E	-	EPS next Y	-2.84	Insider Trans	-0.10%	Shs Float	58.51M	Perf Month	-10.09%
Enterprise Value	4.51B	PEG	-	EPS next Q	-0.66	Inst Own	83.62%	Short Float	15.76%	Perf Quarter	14.65%
Income	-186.75M	P/S	1101.23	EPS this Y	-31.90%	Inst Trans	5.78%	Short Ratio	7.58	Perf Half Y	54.35%
Sales	5.07M	P/B	5.10	EPS next Y	-3.42%	ROA	-20.04%	Short Interest	9.22M	Perf YTD	52.46%
Book/sh	12.41	P/C	5.19	EPS next 5Y	60.72%	ROE	-20.79%	52W High	75.50 -16.16%	Perf Year	154.63%
Cash/sh	12.20	P/FCF	-	EPS past 3/5Y	-46.89% -65.75%	ROIC	-17.00%	52W Low	23.65 167.65%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	176.56% -20.97%	Gross Margin	-63.10%	Volatility	6.83% 4.71%	Perf 5Y	-
Dividend TTM	-	EV/Sales	890.44	EPS Y/Y TTM	-69.02%	Oper. Margin	-4238.99%	ATR (14)	3.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	31.25	Sales Y/Y TTM	666.01%	Profit Margin	-3682.61%	RSI (14)	40.43	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	31.30	EPS Q/Q	-57.52%	SMA20	-6.80%	Beta	0.39	Target Price	90.29
Payout	-	Debt/Eq	0.01	Sales Q/Q	1982.69%	SMA50	-5.86%	Rel Volume	0.54	Prev Close	62.93
Employees	142	LT Debt/Eq	0.01	Earnings	May 08 BMO	SMA200	30.83%	Avg Volume	1.22M	Price	63.30
IPO	Jan 25, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.77% 139.07%	Trades		Volume	657,297	Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	Wolfe Research	Peer Perform
Dec-11-25	Initiated	Wedbush	Outperform	$70
Nov-24-25	Initiated	Truist	Buy
Oct-08-25	Initiated	Guggenheim	Buy	$90
Aug-19-25	Initiated	Piper Sandler	Overweight	$55
Jul-10-25	Resumed	Goldman	Buy	$40
May-02-25	Initiated	JP Morgan	Overweight	$41
Apr-16-25	Initiated	Scotiabank	Sector Perform	$23
Jan-07-25	Initiated	TD Cowen	Buy
Oct-24-24	Initiated	UBS	Buy	$60
Sep-23-24	Initiated	RBC Capital Mkts	Outperform	$66
Aug-28-24	Initiated	ROTH MKM	Buy	$65
Jun-28-24	Initiated	BofA Securities	Buy	$65
Feb-20-24	Initiated	Morgan Stanley	Overweight	$55
Feb-20-24	Initiated	Goldman	Neutral	$42
Feb-20-24	Initiated	Cantor Fitzgerald	Overweight	$75
Feb-14-24	Initiated	H.C. Wainwright	Buy	$75

Show Previous Ratings

Today 08:00AM	SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
May-15-26 08:00AM	CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients (GlobeNewswire)
May-11-26 04:15PM	CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC (GlobeNewswire)
May-08-26 08:30AM	CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
May-05-26 08:00AM	CG Oncology to Present at Upcoming Investor Conferences in May (GlobeNewswire)
03:02AM	Loading…
Mar-08-26 03:02AM	CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026 (MarketBeat)
Mar-06-26 10:22AM	H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating (Insider Monkey)
Mar-02-26 09:27AM	Company News for Mar 2, 2026 (Zacks)
Feb-27-26 08:30AM	CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates (GlobeNewswire)
Feb-23-26 08:00AM	CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire)
Jan-09-26 08:30AM	CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC (GlobeNewswire) +29.26%
Jan-06-26 08:00AM	CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-25 08:00AM	SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
12:20AM	Loading…
Dec-09-25 12:20AM	CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities (Insider Monkey)
Dec-05-25 08:30AM	New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Nov-26-25 07:00AM	CG Oncology Announces New Board Member and Board Transition (GlobeNewswire)
Nov-25-25 04:05PM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting (GlobeNewswire)
Nov-17-25 09:26AM	Company News for Nov 17, 2025 (Zacks)
Nov-14-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.61%
08:00AM	CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-25 08:10AM	ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-17-25 09:55PM	CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim (Insider Monkey) +5.14%
Oct-16-25 04:33PM	Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene (Insider Monkey)
Oct-08-25 06:14PM	Why Cg Oncology Stock Rocketed 7% Higher Today (Motley Fool) +7.13% +9.21%
Sep-22-25 03:19AM	CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment (Insider Monkey)
Sep-19-25 09:20AM	Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? (Zacks)
Sep-18-25 10:03AM	CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire)
07:00AM	Loading…
Sep-05-25 07:00AM	CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months (GlobeNewswire) +6.88%
Sep-03-25 08:00AM	CG Oncology Completes Enrollment in PIVOT-006 (GlobeNewswire)
Aug-29-25 08:00AM	CG Oncology's Executive Leadership to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:14AM	CG Oncology's Bladder Cancer Drug Shows Strong Clinical Data, Drives Optimism Despite Price Target Cut (Insider Monkey)
12:13AM	H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT (Insider Monkey)
Aug-08-25 08:00AM	CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-25 08:40AM	Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates (Zacks) -6.12%
Jul-31-25 11:58AM	CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial (Insider Monkey)
Jul-29-25 04:05PM	Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals (GlobeNewswire)
Jul-07-25 08:30AM	Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs (PR Newswire)
Jul-06-25 04:15AM	Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating (Insider Monkey)
Jul-01-25 02:30PM	Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors (PR Newswire)
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire)
Jun-05-25 08:00AM	CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 08:46AM	CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success (Zacks)
May-15-25 08:00AM	CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-14-25 09:38AM	Company News for May 14, 2025 (Zacks)
May-13-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:45AM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:00AM	SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
Apr-29-25 09:10AM	CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? (Zacks)
02:02AM	Why CG Oncology, Inc. (CGON) Surged on Monday (Insider Monkey)
Apr-28-25 04:05PM	CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily) +25.03%
11:14AM	CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why (Benzinga)
10:24AM	CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily)
Apr-26-25 04:10PM	CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting (GlobeNewswire)
Apr-24-25 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 (GlobeNewswire)
Apr-11-25 05:30AM	How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs (The Wall Street Journal) +9.36%
Apr-02-25 12:32PM	CG Oncology Looks Attractive At Current Prices (Rating Upgrade) (Seeking Alpha)
Mar-31-25 09:55AM	Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade (Zacks) -7.31%
08:00AM	CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates (GlobeNewswire)
05:54AM	Company News for Mar 31, 2025 (Zacks)
Mar-28-25 07:00AM	CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates (GlobeNewswire)
Mar-26-25 05:45PM	Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? (Insider Monkey)
Mar-24-25 08:00AM	Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy (GlobeNewswire) +5.47%
Mar-12-25 08:00AM	CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates (GlobeNewswire)
Feb-26-25 08:00AM	CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-25-25 09:49AM	Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now? (Insider Monkey) -6.65%
Feb-23-25 01:29PM	Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:19PM	Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now (Insider Monkey)
Jan-16-25 09:55AM	Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect? (Zacks)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal) +5.35%
Dec-16-24 04:05PM	CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-12-24 08:19PM	CG Oncology Announces Pricing of Public Offering (GlobeNewswire) -9.01%
Dec-11-24 06:17AM	CG Oncology Announces Proposed Public Offering (GlobeNewswire) -5.85%
Dec-06-24 08:00AM	SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
07:10AM	CG Oncology announces data from Phase 3 BOND-003 trial (TipRanks)
Dec-05-24 11:35AM	CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate (Benzinga) -6.54%
07:00AM	Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Dec-02-24 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024 (GlobeNewswire)
Nov-20-24 08:00AM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting (GlobeNewswire)
Nov-12-24 08:00AM	CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.83%
Nov-11-24 08:00AM	CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer (GlobeNewswire)
Sep-14-24 05:25PM	Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Aug-30-24 08:00AM	CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-08-24 08:23AM	CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +7.02%
Jun-18-24 08:00AM	CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec (GlobeNewswire)
Jun-06-24 12:14PM	CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC (GlobeNewswire)
May-24-24 08:00AM	CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting (GlobeNewswire) +9.07%
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 01:54PM	CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 (InvestorPlace) -7.43%
08:00AM	CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-03-24 11:23AM	Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire) -8.18%
Apr-26-24 08:00AM	CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 (GlobeNewswire) +13.26%
Apr-24-24 10:00AM	CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire)
Apr-11-24 10:02PM	20 Countries with the Most Domestically Listed Companies in the World (Insider Monkey)
Mar-28-24 08:00AM	CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting (GlobeNewswire) +7.07%

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Chairman & CEOMr. Arthur Kuan

President & COOMr. Ambaw Bellete M.S.

Chief Financial OfficerMr. James M. DeTore

General CounselMr. Joshua F. Patterson

Chief Medical OfficerDr. Vijay Kasturi M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mulay James	Director	Apr 17 '26	Option Exercise	36.63	15,600	571,428	15,600	Apr 20 04:15 PM
Mulay James	Director	Apr 17 '26	Sale	73.01	15,600	1,138,956	0	Apr 20 04:15 PM
JAMES MULE	Director	Apr 17 '26	Proposed Sale	66.34	17,564	1,165,196		Apr 17 04:34 PM
Mulay James	Director	Mar 16 '26	Option Exercise	9.64	1,964	18,926	1,310	Mar 17 04:15 PM
Mulay James	Director	Mar 16 '26	Sale	63.50	1,964	124,714	0	Mar 17 04:15 PM
Kuan Arthur	Chief Executive Officer	Mar 12 '26	Option Exercise	1.72	64,612	111,133	200,763	Mar 13 04:09 PM
Kuan Arthur	Chief Executive Officer	Mar 04 '26	Option Exercise	1.72	102,871	176,938	139,022	Mar 06 05:52 PM
Mulay James	Director	Jan 09 '26	Option Exercise	12.07	11,145	134,515	10,491	Jan 13 04:15 PM
Mulay James	Director	Jan 09 '26	Sale	52.47	11,145	584,799	0	Jan 13 04:15 PM
JAMES MULAY	Director	Jan 09 '26	Proposed Sale	41.93	13,109	549,660		Jan 09 04:32 PM
POST LEONARD E	Director	Nov 17 '25	Option Exercise	0.60	1,000	600	1,000	Nov 18 04:30 PM
POST LEONARD E	Director	Nov 17 '25	Sale	41.43	1,000	41,430	0	Nov 18 04:30 PM
POST LEONARD E	Director	Oct 13 '25	Option Exercise	0.60	1,000	600	1,000	Oct 15 04:15 PM
POST LEONARD E	Director	Oct 13 '25	Sale	43.25	1,000	43,250	0	Oct 15 04:15 PM
Mulay James	Director	Oct 09 '25	Option Exercise	3.72	5,903	21,959	5,903	Oct 10 04:15 PM
Mulay James	Director	Oct 09 '25	Sale	43.99	5,903	259,673	0	Oct 10 04:15 PM
JAMES MULAY	Director	Oct 09 '25	Proposed Sale	40.71	6,557	266,935		Oct 09 04:19 PM
POST LEONARD E	Director	Sep 30 '25	Option Exercise	0.60	5,000	3,000	5,000	Oct 01 05:07 PM
POST LEONARD E	Director	Sep 30 '25	Sale	40.09	5,000	200,450	0	Oct 01 05:07 PM
Mulay James	Director	Sep 29 '25	Option Exercise	1.82	12,755	23,214	12,755	Sep 30 04:38 PM
Mulay James	Director	Sep 29 '25	Sale	39.19	12,755	499,868	0	Sep 30 04:38 PM
LEONARD E POST	Director	Sep 30 '25	Proposed Sale	39.08	5,000	195,400		Sep 30 04:27 PM
Mulay James	Director	Sep 18 '25	Option Exercise	1.82	19,112	34,784	19,112	Sep 22 07:30 AM
Mulay James	Director	Sep 19 '25	Option Exercise	1.82	3,574	6,505	3,574	Sep 22 07:30 AM
Mulay James	Director	Sep 18 '25	Sale	39.01	19,112	745,559	0	Sep 22 07:30 AM
Mulay James	Director	Sep 19 '25	Sale	38.99	3,574	139,350	0	Sep 22 07:30 AM
JAMES MULAY	Director	Sep 18 '25	Proposed Sale	37.72	35,441	1,336,835		Sep 18 04:28 PM
POST LEONARD E	Director	Sep 15 '25	Option Exercise	0.60	1,000	600	1,000	Sep 16 04:15 PM
POST LEONARD E	Director	Sep 15 '25	Sale	35.10	1,000	35,100	0	Sep 16 04:15 PM
LEONARD E POST	Director	Sep 15 '25	Proposed Sale	33.34	3,000	100,020		Sep 15 04:30 PM
Liu Brian Guan-Chyun	Director	Sep 11 '25	Buy	33.00	1,515,151	49,999,983	1,515,151	Sep 15 08:32 AM
Mulay James	Director	Sep 05 '25	Option Exercise	0.60	27,015	16,209	27,015	Sep 08 04:16 PM
Mulay James	Director	Sep 05 '25	Sale	31.53	27,015	851,797	0	Sep 08 04:16 PM
JAMES MULAY	Director	Sep 05 '25	Proposed Sale	30.94	27,015	835,844		Sep 05 04:24 PM
Song Hong Fang	Director	Sep 03 '25	Sale	27.80	100,000	2,779,542	2,903,931	Sep 04 05:00 PM
POST LEONARD E	Director	Sep 03 '25	Option Exercise	0.60	1,000	600	1,000	Sep 04 04:30 PM
POST LEONARD E	Director	Sep 03 '25	Sale	28.00	1,000	28,000	0	Sep 04 04:30 PM
Charming Jade Ltd	Director	Sep 03 '25	Proposed Sale	27.46	100,000	2,746,000		Sep 03 05:06 PM
LEONARD E POST	Director	Sep 03 '25	Proposed Sale	27.46	1,000	27,460		Sep 03 04:29 PM
POST LEONARD E	Director	Jul 17 '25	Option Exercise	0.60	2,000	1,200	2,000	Jul 18 04:30 PM
POST LEONARD E	Director	Jul 17 '25	Sale	28.00	2,000	56,000	0	Jul 18 04:30 PM
LEONARD E POST	Director	Jul 17 '25	Proposed Sale	26.08	2,000	52,160		Jul 17 04:22 PM
POST LEONARD E	Director	May 21 '25	Option Exercise	0.60	1,000	600	1,000	May 22 04:15 PM
POST LEONARD E	Director	May 21 '25	Sale	28.00	1,000	28,000	0	May 22 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGON

Cg Oncology Inc

Upgrade your Finviz experience